How To Restructure: Admedus Opts For A Restart

20 Dec 2016

Admedus and its product mix was an unfolding success story – and still is, due to a restructuring of activities and a resetting of aims that have ensured the Australia-US tissue engineering company does not miss out on the opportunities it has crafted for itself. Chairman and interim CEO Wayne Paterson explains what changes were required and why.

Recent In Vivo interviews with executives from the Australian Stock Exchange-listed tissue devices and therapeutic vaccines innovator Admedus Ltd. (ASX: AHZ) have described a company with a unique business model and product mix that is on the cusp of major market success in more than one area. (Also see "Marketing Efforts Pay Off As Admedus Ups CardioCel Centers By 50%" - In Vivo, 23 March, 2016.)

Its potential is both compelling and undeniable, but the buzz about Admedus' pace of progress took on a different tone...